Healthcare Industry News: myelofibrosis
News Release - October 22, 2012
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial OfficerWILMINGTON, Del.--(Healthcare Sales & Marketing Network)--Incyte Corporation (INCY) today announced that Jim Daly has joined Incyte as Executive Vice President and Chief Commercial Officer, reporting to Paul Friedman, M.D., Incyte's President and Chief Executive Officer. Formerly Senior Vice President, North America Commercial Operations at Amgen, Mr. Daly is joining Incyte effective today and will serve on the executive leadership team, assuming responsibility for Incyte’s commercial organization, including sales, marketing and business development.
“Jakafi is a novel, first-in-class product that is making a remarkable difference for patients with this debilitating condition,” stated Mr. Daly. “I’m excited by Incyte’s cutting-edge science and the potential commercial value of its substantial pipeline. Incyte’s leadership position in the development of oral JAK inhibitors to address unmet needs in a wide range of grievous illnesses represents a unique opportunity. I look forward to joining the team, building on its success with Jakafi and contributing to the development and commercialization of Incyte’s future products.”
Prior to joining Incyte, Mr. Daly held multiple leadership positions at Amgen, Inc. In his last role, Mr. Daly was Senior Vice President, responsible for North America Commercial Operations as well as Global Marketing and Commercial Development. From 2001 to 2005, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. During his time at Amgen, his teams were responsible for the successful launch of many oncology products, including Aranesp®, Neulasta®, Vectibix®, Nplate® and, most recently, Xgeva®.
Previously, Mr. Daly spent 17 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he advanced through numerous positions of increasing responsibility in the United States and abroad. Mr. Daly earned his undergraduate degree in Pharmacy and his Master’s degree in Business Administration from the State University of New York in Buffalo.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for inflammation and oncology, including products for myelofibrosis. For additional information about Incyte, please visit www.incyte.com.
Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.
Important Safety Information
Jakafi can cause serious side effects including:
Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests.
Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.
The most common side effects of Jakafi include dizziness and headache.
These are not all the possible side effects of Jakafi. Ask your healthcare provider or pharmacist for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.
Before taking Jakafi, tell your healthcare provider about all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had liver or kidney problems, are on dialysis, or have any other medical condition. Talk to your healthcare provider before drinking grapefruit juice while taking Jakafi.
Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.
For Full Prescribing Information for Jakafi, visit www.Jakafi.com.
Except for the historical information set forth herein, the matters set forth in this press release, including without limitation statements with respect to our plans and expectations with respect to Jakafi® (ruxolitinib), including the potential efficacy and therapeutic and commercial value of Jakafi, and the advancement of our pipeline, contain predictions, estimates and other forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of Jakafi, the high degree of risk and uncertainty associated with drug development and the regulatory approval process, and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended June 30, 2012. Incyte disclaims any intent or obligation to update these forward-looking statements.
Jakafi is a registered trademark of Incyte Corporation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.